
IMAB
Healthcare · Biotechnology · $533.7M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2025
EPS trend, 90 days to now · +14.3% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 1, 2026 | Time not confirmed | -0.22 | 0.00 | +100.0% |
| Oct 6, 2025 | Time not confirmed | -0.04 | -0.07 | -75.0% |
| Aug 20, 2025 | Time not confirmed | -0.04 | -0.07 | -75.0% |
| Apr 3, 2025 | Time not confirmed | -0.06 | -0.06 | +8.3% |
| Mar 12, 2025 | After the close | -0.05 | -0.06 | -20.0% |
| Nov 14, 2024 | Time not confirmed | -0.07 | -0.11 | -57.1% |
| Aug 28, 2024 | Time not confirmed | -0.31 | -0.09 | +71.0% |
| Jun 5, 2024 | Before the open | -0.12 | -0.22 | -78.4% |
| Mar 14, 2024 | Time not confirmed | -0.48 | -0.48 | -0.2% |
| Nov 29, 2023 | Time not confirmed | -0.13 | 0.00 | +100.0% |
| Aug 17, 2023 | Before the open | -0.78 | -0.56 | +28.7% |
| May 31, 2023 | Time not confirmed | -0.14 | -0.14 | +0.2% |
| Mar 31, 2023 | Before the open | -0.49 |
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It…
| -1.01 |
| -106.1% |
| Nov 30, 2022 | Time not confirmed | -0.46 | -0.46 | -1.0% |
| Aug 30, 2022 | Before the open | -1.24 | -0.99 | +20.2% |
| Jun 1, 2022 | Time not confirmed | -0.45 | -0.45 | -0.8% |
| Mar 29, 2022 | Before the open | -0.48 | 0.00 | +100.0% |
| Dec 1, 2021 | Time not confirmed | -0.24 | -0.24 | +0.4% |
| Aug 31, 2021 | Before the open | -0.99 | -0.99 | 0.0% |
| Jun 2, 2021 | Time not confirmed | -0.36 | -0.36 | -0.6% |
| Mar 29, 2021 | Before the open | 0.91 | 0.85 | -6.1% |
| Dec 2, 2020 | Time not confirmed | 0.70 | 0.70 | -0.4% |
| Aug 31, 2020 | Before the open | -0.53 | -0.53 | 0.0% |